Pimavanserin Capsule
Product Images NDC 72205-055

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Pimavanserin (NDC 72205-055). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pimavanserin-caps-34mg-30s-container-label (Pimavanserin Caps 34mg 30s Container Label)

Pimavanserin-caps-34mg-30s-container-label (Pimavanserin Caps 34mg 30s Container Label)
This text provides information on a medication called Pimavanserin, which comes in capsule form containing 34 mg of pimavanserin. The usual recommended dosage is one capsule per day, with or without food. It is essential to refer to the package insert for comprehensive prescribing information. The medication should be stored at temperatures between 20°C to 25°C (68°F to 77°F). The manufacturer is MSN Pharmaceuticals Inc, based in Piscataway, NJ, with distribution by Novadoz Pharmaceuticals LLC. Contact information for Novadoz Pharmaceuticals includes a telephone number: 855-NOVADOZ. It is crucial to keep this medication out of the reach of children.*
FDA Label Image

Pimavanserin-figure-1 (Pimavanserin Figure 1)

Pimavanserin-figure-1 (Pimavanserin Figure 1)
This text provides information on hepatic impairment, categorizing it as mild, moderate, or severe. It also mentions "Fold Change and 90% CI" in relation to the reference value.*
FDA Label Image

Pimavanserin-figure-2 (Pimavanserin Figure 2)

Pimavanserin-figure-2 (Pimavanserin Figure 2)
This text appears to be a list of medications or substances along with their relation to certain enzymes or effects on the body. It mentions Dopaminergic Agent: PK, carbidopa-levodopa, CYP3AY Substrate, midazolam, and Fald Change based on 90% CI. It seems to be related to pharmacological studies or drug interactions.*
FDA Label Image

Pimavanserin-figure-3 (Pimavanserin Figure 3)

FDA Label Image

Pimavanserin-figure-4 (Pimavanserin Figure 4)

FDA Label Image

Pimavanserin-figure-5 (Pimavanserin Figure 5)

FDA Label Image

Pimavanserin-structure (Pimavanserin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.